What is Editas Medicine Inc (EDIT) stock price today?

Editas Medicine Inc (EDIT) currently trades at $2.82 per share. The stock has a market capitalization of $284.81M and a P/E ratio of —x.

Is EDIT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Editas Medicine Inc has a Smart Value Score of 20/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Editas Medicine Inc's revenue and earnings?

Editas Medicine Inc has trailing twelve-month (TTM) revenue of $40.52M with profit margins of 0.00%. Earnings per share (EPS) is $-1.80.

EDIT

Editas Medicine Inc

NASDAQ: EDIT · HEALTHCARE · BIOTECHNOLOGY

$2.82

-7.84% today

Updated 2026-04-29

Market cap

$284.81M

P/E ratio

—

P/S ratio

7.03x

EPS (TTM)

$-1.80

Dividend yield

—

52W range

$1 – $5

Volume

1.7M

Market cap

$284.81M

P/E ratio

—

P/S ratio

7.03x

EPS (TTM)

$-1.80

Dividend yield

—

52W range

$1 – $5

Volume

1.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$5.72

+102.84%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy7 Buy5 Hold0 Sell2 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-36.45M

- Revenue declining -19.20% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$19.71M	$78.12M	$32.31M	$40.52M	$40.52M
Net income	$-204.35M	$-153.22M	$-237.09M	$-160.06M	$-5.62M
EPS	—	—	—	—	$-1.80
Free cash flow	$-181.47M	$-136.90M	$-219.11M	$-165.85M	$-36.45M
Profit margin	-1,036.69%	-196.13%	-733.72%	-395.01%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-12	PARISON, AMY	Buy	292,856	—
2026-03-12	O'NEILL, GILMORE NEIL	Buy	1,015,200	—
2026-03-12	BURKLY, LINDA	Buy	292,856	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
EDIT	$284.81M	20	5.3	2.5	5.0	5.0	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Editas Medicine Inc trades at $2.82. Our Smart Value Score of 20/100 indicates the stock is weak. TTM revenue stands at $40.52M.

Frequently asked questions

What is Editas Medicine Inc's stock price?

Editas Medicine Inc (EDIT) trades at $2.82.

Is Editas Medicine Inc overvalued?

Smart Value Score 20/100 (Grade F, Strong Sell).

What is the price target of Editas Medicine Inc (EDIT)?

The analyst target price is $5.72, representing +102.8% upside from the current price of $2.82.

What is Editas Medicine Inc's revenue?

TTM revenue is $40.52M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio7.03x

ROE-198.10%

Beta2.04

50D MA$2.49

200D MA$2.65

Shares out0.10B

Float0.10B

Short ratio—

Avg volume1.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

EDIT vs LLY →EDIT vs JNJ →EDIT vs ABBV →Stock screener →